Posted by Michael Wonder on 16 Jul 2018
Tonix Pharmaceuticals receives fast track designation from the U.S. FDA for TNX-102 SL for treatment of agitation in Alzheimer’s disease
16 July 2018 - Tonix Pharmaceuticals today announced that the U.S. FDA has granted fast track designation to its investigational new drug, TNX-102 SL, for the treatment of agitation in Alzheimer’s disease.
The same drug, TNX-102 SL, or Tonmya, for the treatment of post-traumatic stress disorder (PTSD), has previously been designated as a Breakthrough Therapy by the FDA. It is currently in a Phase 3 study for military-related PTSD, with an interim analysis expected in the third quarter of 2018.
